Summary: Developmem ofheart failure (HF) or left ventri cular systolic dysfunction (LVSD) significantlyincreases mortality post acute myocardial infarction (A.MI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make cìinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potenti al barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HP is presented.
Aldosterone blockade in post-acute myocardial infarction heart failure
FERRARI, Roberto;
2006
Abstract
Summary: Developmem ofheart failure (HF) or left ventri cular systolic dysfunction (LVSD) significantlyincreases mortality post acute myocardial infarction (A.MI). Aldosterone contributes to the development and progression of HF post AMI, and major guidelines now recommend aldosterone blockade in this setting. However, lack of practical experience with aldosterone blockade may make cìinicians hesitant to use these therapies. This review is based on a consensus cardiology conference that occurred in May 2005 (New York City) concerning these topics. Potenti al barriers to the use of aldosterone blockade are discussed and an algorithm for appropriate in-hospital pharmacologic management of AMI with LVSD and/or HP is presented.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
